RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Moyamoya Disease: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Comparison of outcomes after direct extracranial-to-intracranial bypass for moyamoya disease and non-moyamoya pathology: A systematic review and meta-analysis.
Manalil Noel F et al., Neurosurgical review (19 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42894060/
- 2.
Factors Associated with Functional Decline After Direct Bypass Surgery for Moyamoya Disease: A Nationwide Multicenter Retrospective Cohort Study Research Article
Eiichi Baba et al., Research Square (18 October 2026)
https://doi.org/10.21203/rs.3.rs-11005927/v1
- 3.
Modeling Moyamoya disease using patient-derived induced pluripotent stem cells and organoids.
Kim Jong-Tae et al., Molecular biology reports (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42886421/
- 4.
Association of Perioperative Hematocrit With Postoperative Neurological Complications in Adults Undergoing Revascularization Surgery for Moyamoya Disease: A Retrospective Cohort Study.
Sim Ji H et al., Journal of neurosurgical anesthesiology (15 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42878103/
- 5.
Management and Long-Term Outcomes of Peripheral Cerebral Aneurysms Associated with Moyamoya Disease: A Single-Center Case Series
Makoto Mizushima et al., Research Square (14 October 2026)
https://doi.org/10.21203/rs.3.rs-10976871/v1
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Moyamoya Disease
Moyamoya disease is a rare condition in which the large arteries at the base of the brain slowly narrow, and a network of small, fragile vessels forms to compensate. It can cause strokes, mini-strokes and seizures in children and adults. Treatment includes surgery to improve blood flow to the brain and medicines to lower stroke risk.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Extracranial-intracranial (EC-IC) bypass is an established technique to augment intracranial flow in patients with moyamoya disease (MMD) and other steno-occlusive diseases. The outcomes after direct EC-IC bypass for MMD compared to non-MMD pathologies (N-MMD) have not been systematically reviewed or compared in a meta-analysis. We performed a systematic review and meta‑analysis of studies reporting on outcomes in adults undergoing EC-IC bypass stratified by indication. Patients were assigned to either MMD or N-MMD pathologies with the latter primarily consisting of intracranial atherosclerotic disease (ICAD) and extracranial carotid occlusion (CO). Outcomes include graft patency, postoperative stroke or intracranial hemorrhage (ICH), and hyperperfusion syndrome (HPS). Random effects models were used to obtain pooled estimates for each outcome. Seventeen studies met inclusion criteria comprising 1,354 patients and 1,451 hemispheres. The weighted mean age was 49.1 years and 56.7% of patients were female. The indications for bypass included MMD or MMS in 52.6% of patients. ICAD and CO comprised 46.3% and 3.1% of patients, respectively. There was no difference in graft patency rates for the MMD and N-MMD groups (OR 0.81, 95% CI 0.54-1.21; I2 = 0%). There was also no difference in postoperative stroke (OR 0.68, 95% CI 0.33-1.41; I2 = 23%) or ICH (OR 1.46, 95% CI 0.34-6.26; I2 = 61.4%). There was no significant difference in the rate of HPS between the N-MMD and MMD groups (OR 1.69, 95% CI 0.67-4.26; I2 = 0). This meta-analysis discovered no significant differences in technical and postoperative outcomes between direct EC-IC bypass procedures performed for moyamoya and those performed for non-moyamoya steno-occlusive diseases. Further research with large multicenter cohorts, standardized techniques, and consistent outcome reporting is required to confirm these results.
Common Questions
What is Moyamoya Disease?
Moyamoya disease is a rare condition in which the large arteries at the base of the brain slowly narrow, and a network of small, fragile vessels forms to compensate. It can cause strokes, mini-strokes and seizures in children and adults. Treatment includes surgery to improve blood flow to the brain and medicines to lower stroke risk.
How many clinical trials are available for Moyamoya Disease?
RareWays currently indexes 32 clinical trials for Moyamoya Disease, of which 7 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Moyamoya Disease come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Moyamoya Disease.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.